PolyPid company info

What does PolyPid do?
PolyPid (NASDAQ:PYPD) specializes in developing extended-release drugs with a primary focus on preventing surgical site infections and promoting bone growth. The company is recognized for its innovative PLEX technology platform, a unique delivery system that allows for a controlled release of drugs over extended periods, improving patient outcomes and reducing healthcare costs. Through its flagship projects, D-PLEX100 for surgical site infections and BONEX for bone regeneration, PolyPid aims to address critical unmet medical needs in the surgical and orthopedic sectors. Its mission is centered on enhancing recovery and reducing complications associated with surgeries, thereby improving the quality of life for patients worldwide.
PolyPid company media
Company Snapshot

Is PolyPid a public or private company?

key
Ownership
Public

How many people does PolyPid employ?

people
Employees
61

What sector is PolyPid in?

pie chart
Sector
Health Care

Where is the head office for PolyPid?

location pin
Head Office
Petah Tikva, Israel

What year was PolyPid founded?

founded flag
Year Founded
2008
What does PolyPid specialise in?
/Drug Delivery /Prolonged Release /Bone Regeneration /Infection Prevention /Surgical Site Infections /Post-Surgical Complications

What are the products and/or services of PolyPid?

Overview of PolyPid offerings
D-PLEX100, a sustained release antibiotic for the prevention of surgical site infections.
D-PLEX100 for the prevention of abdominal colonic surgery infections.
Local anesthetic product line for post-surgical pain management.
Oncology pipeline aimed at solid tumor indications through controlled release of chemotherapeutic agents.
Polymer-based formulation technology for enhanced drug delivery in various medical applications.

Who is in the executive team of PolyPid?

PolyPid leadership team
  • Ms. Dikla  Czaczkes Akselbrad
    Ms. Dikla Czaczkes Akselbrad
    CEO & Director
  • Mr. Jonny  Missulawin
    Mr. Jonny Missulawin
    Chief Financial Officer
  • Ms. Dalit  Hazan
    Ms. Dalit Hazan
    Executive Vice President of R&D and Clinical & Regulatory Affairs
  • Mr. Ori  Warshavsky
    Mr. Ori Warshavsky
    Chief Operating Officer - US
  • Ms. Maria  Rubin
    Ms. Maria Rubin
    Vice President of Operations
  • Mr. Tal  Vilnai
    Mr. Tal Vilnai
    General Counsel & Corporate Secretary
  • Ms. Rivi  Lev-ari
    Ms. Rivi Lev-ari
    Vice President of Human Resource
  • Dr. Jean-Marc  Hagai Pharm.D.
    Dr. Jean-Marc Hagai Pharm.D.
    Chief Commercial Officer